Mentice (MNTC) Q1 2025 earnings summary

Executive summary

• Net sales increased by 19.5% year-over-year to SEK 54.3 million, with 17.3% organic growth and strong contributions from all regions, especially Americas and APAC.

• Order intake rose 15.1% to SEK 43.7 million, mainly driven by the Medical Device Industry (MDI) segment and Americas region.

• EBITDA was -SEK 19.2 million, impacted by SEK 3.5 million in one-off restructuring costs and SEK 5 million from currency effects.

• Business development focused on streamlining operations, consolidating production in Denver, and integrating acquisitions like Ankyros.

• CEO transition announced, with Frans Venker appointed as new CEO effective January 1, 2025.

Financial highlights

• Gross margin improved to 92.4% from 92.0% year-over-year.

• Operational cash flow was negative at SEK 3.3 million.

• Cash at period end was SEK 40.6 million, down from SEK 57.5 million a year earlier.

• Equity/asset ratio declined to 38.7% from 45.4% year-over-year.

• Order book at quarter end was SEK 117.9 million, with SEK 75 million scheduled for 2025.

Outlook and guidance

• Market conditions are more challenging due to potential tariffs, FX volatility, and a strengthening Swedish Krona.

• Production and supply chain are being adjusted to mitigate tariff and FX risks.

• Company expects continued growth opportunities in simulation for image-guided interventional therapies, focusing on product development and Americas expansion.

• Growth projections for the year remain unchanged despite macroeconomic uncertainties.

• Strategic goal to reach 20–30% annual net sales growth and a 20% EBITDA margin within three years.